Navigation Links
IVCC develops new public health insecticides
Date:11/21/2010

The Innovative Vector Control Consortium (IVCC) has received $50 million from the Bill & Melinda Gates Foundation to continue its work to develop new insecticides for the improved control of mosquitoes and other insects which transmit malaria, dengue and other neglected tropical diseases.

IVCC was established in 2005 with an initial grant of $50.7 million over five years from the foundation. Since then, an unprecedented development pipeline of new, reformulated and repurposed insecticides has been established in partnership projects with leading global chemical companies. A suite of information systems and diagnostic tools for the more effective and efficient use of insecticides has also been developed, with these products now nearing the end of their development phase and being readied for rollout in the coming year.

The new five year grant will support new and ongoing projects to develop new Active Ingredients for insecticides and to complete the existing portfolio of insecticide formulation and repurposing projects.

Chief Executive Officer Professor Janet Hemingway explained: "The need for new insecticides has never been greater. Increased funding for control programmes is saving thousands of lives but malaria is still killing one child in Africa every 45 seconds. Resistance to insecticides is increasing at an alarming rate and we must find new alternatives even if we are to stay still in our battle against this and other vector borne diseases.

"This award allows us continue the pioneering work we're doing in partnership with the chemical industry to find and develop totally new classes of insecticide to help put an end to this needless loss of life. Our strategic aim is to provide three new Active Ingredients for use in public health insecticides by 2020."


'/>"/>

Contact: Alan Hughes
a.p.hughes@liv.ac.uk
44-151-705-3308
Liverpool School of Tropical Medicine
Source:Eurekalert

Page: 1

Related biology news :

1. NC State develops more precise genetic off switches
2. Yale develops new animal model for hemophilia A
3. Research develops simple recipe for fungus-free horseradish
4. CCNY-led team develops non-toxic oil recovery agent
5. Harvards Wyss Institute develops technology to produce sugar from photosynthetic bacteria
6. ISU researcher develops green, bio-based process for producing fuel additive
7. Military develops multi-purpose green decontaminants for terrorist attack sites
8. CSIRO develops highest-yielding salt-tolerant wheat
9. Tiny gold probes give scientists a sense of how disease develops
10. University of the Basque Country develops system for identifying illnesses in Paraguay
11. New strategy develops 2 prototype drugs against cancer, retinal diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
(Date:11/29/2016)... France , November 29, 2016 Nearly one ... Continue Reading ... ... is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This ... products engineered to radically streamline culture processes, minimize processing time, significantly decrease ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
(Date:12/7/2016)... 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces ... at the Company,s Annual and Special Meeting. ... place on Thursday, December 15, 2016 at Mount ... EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta ... meeting and management information circular, containing the matters to be ...
Breaking Biology Technology: